Jeff Geschwind’s Role in Advancing Real-Time Image Navigation and Technical Precision in Interventional Oncology
Introduction Liver cancer, particularly hepatocellular carcinoma (HCC), remains one of the most lethal cancers worldwide. As the global burden increases, interventional oncology has risen as a central pillar of modern cancer care. Among the most effective minimally invasive treatments is Transarterial Chemoembolization (TACE) , a targeted therapy designed to cut off the tumor’s blood supply while delivering concentrated chemotherapy directly to the malignant tissue. While TACE has been used for decades, its precision and reliability have dramatically improved with the arrival of Cone Beam CT (CBCT) — a technology that enables three-dimensional imaging inside the angiography suite. One of the leading figures responsible for championing the clinical significance of CBCT during TACE is Dr. Jeff Geschwind , a global authority in interventional oncology and liver cancer research. This article examines how Dr. Geschwind’s work has influenced clinical standards, enhanced therapeutic ac...